Opinion

Video

Clinical Efficacy of Non-Statin Treatment Options in ASCVD

Author(s):

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP

Focusing on PCSK9 inhibitors, inclisiran, and bempedoic acid, the panel compares treatment efficacy and outlines patient factors that influence treatment decisions.

Related Videos
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
Related Content
ACC 2025: Intravenous Iron Safe, but Results in Mixed Findings for Patients With Heart Failure
March 30th 2025

ACC 2025: Intravenous Iron Safe, but Results in Mixed Findings for Patients With Heart Failure

Aislinn Antrim, Managing Editor
Introducing the Tell-Tale Heart Podcast
March 25th 2025

Introducing the Tell-Tale Heart Podcast

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
ACC 2025: Dapagliflozin Found Safe, Effective in Older Adults With Heart Failure Undergoing Valve Replacement
March 29th 2025

ACC 2025: Dapagliflozin Found Safe, Effective in Older Adults With Heart Failure Undergoing Valve Replacement

Aislinn Antrim, Managing Editor
ACC 2025: Rivaroxaban Comparable to Warfarin in Left Ventricular Blood Clots
March 29th 2025

ACC 2025: Rivaroxaban Comparable to Warfarin in Left Ventricular Blood Clots

Aislinn Antrim, Managing Editor
ACC 2025: Lower-Dose Apixaban Is Effective, Safer Than Full Dose for Preventing VTE Recurrence in Patients With Cancer
March 29th 2025

ACC 2025: Lower-Dose Apixaban Is Effective, Safer Than Full Dose for Preventing VTE Recurrence in Patients With Cancer

Aislinn Antrim, Managing Editor
ACC 2025: Semaglutide Significantly Improves Walking Distance, Symptoms, QOL for Individuals with PAD and Diabetes
March 29th 2025

ACC 2025: Semaglutide Significantly Improves Walking Distance, Symptoms, QOL for Individuals with PAD and Diabetes

Aislinn Antrim, Managing Editor